2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Thermo Fisher Scientific Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #45 · 賽默飛世爾科技公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | TMO |
| Company | Thermo Fisher Scientific Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #45 · 0.37% (Oct 28, 2026) |
| Sector rank | #6 in Health Care (Oct 28, 2026) |
| Headquarters | Waltham, Massachusetts |
| Founded | 1956 |
| CEO | Marc N. Casper (Chairman, President and CEO) |
| Employees | Approximately 125,000 (FY2024) |
| Market cap | $260.36B (Oct 30, 2026) |
| Share price | $697.00 (Oct 30, 2026 close) |
| SEC filings | EDGAR — CIK 0000097745 |
WHAT IT DOES
Thermo Fisher Scientific supplies the tools and services behind life sciences research, drug development and clinical diagnostics. Its one-line model: sell instruments, reagents and consumables, and run the laboratory and pharma services that turn them into results.
Revenue comes from products used in research and production and from services including contract development, manufacturing and clinical research. Customers are pharmaceutical and biotechnology companies, academic and government laboratories, hospitals and industrial users.
The economics mix recurring consumables with capital equipment: instruments are lumpy, while reagents, service contracts and outsourced pharma work recur, so the blend steadies revenue through research funding cycles.
BUSINESS SEGMENTS
| Life Sciences Solutions | Reagents, instruments and consumables for biological and medical research, drug discovery and production. |
| Analytical Instruments | Instruments, consumables, software and services for pharmaceutical, biotechnology, academic, government and industrial markets. |
| Specialty Diagnostics | Clinical diagnostics products including immunodiagnostics, microbiology and transplant diagnostics. |
| Laboratory Products and Biopharma Services | Laboratory equipment, research and safety market channels, and pharma services and clinical research. |
HISTORY
| Year | Milestone |
|---|---|
| 1956 | Thermo Electron is founded. |
| 2006 | Thermo Electron merges with Fisher Scientific to form Thermo Fisher Scientific. |
| 2024 | Thermo Fisher completes the acquisition of Olink, a proteomics solutions provider. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $44.56B (FY2025 revenues) |
| Operating income | $7.75B (FY2025 GAAP operating income) |
| Net income | $6.70B (FY2025 GAAP net income attributable) |
| Diluted EPS | $17.74 (FY2025 GAAP diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Thermo Fisher Scientific is a mid-weight health care constituent: rank #45 by weight at 0.37% as of Oct 28, 2026, and #6 in Health Care. Its orders and service volumes are read as a gauge of life sciences research spending, and through it of drug development activity across the sector.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Thermo Fisher Scientific 2024 results release (January 30, 2025) and 2024 Form 10-K |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 28, 2026 close, fetched Oct 29, 2026 |
| Market cap | $260.36B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | TMO |
| 公司 | Thermo Fisher Scientific(賽默飛世爾科技) |
| GICS 板塊/行業 | 醫療保健(XLV)/生命科學工具與服務 |
| 標普500排名(按權重) | #45 · 0.37%(Oct 28, 2026) |
| 板塊內排名 | 醫療保健 #6(Oct 28, 2026) |
| 總部 | 美國麻薩諸塞州沃爾姆 |
| 成立 | 1956年 |
| 執行長 | Marc N. Casper(董事長兼總裁兼執行長) |
| 員工 | 約 125,000 人(2024 年) |
| 市值 | $260.36B(Oct 30, 2026) |
| 股價 | $697.00(Oct 30, 2026 收盤) |
| SEC 申報 | EDGAR — CIK 0000097745 |
業務概覽
Thermo Fisher Scientific 提供生命科學研究、藥物開發與臨床診斷背後的工具與服務。其一句話商業模式是:售賣儀器、試劑與耗材,並運營將其轉化為成果的實驗室與藥品服務。
收入來自研究與生產用產品與服務,包括委託開發、製造與臨床研究。客戶為藥品與生物技術公司、學術與政府實驗室、醫院與工業用戶。
這種經濟混合經常性耗材與資本設備:儀器訂單波動大,而試劑、服務合約與外包藥品工作反覆發生,故組合可在研究經費週期中穩定收入。
業務板塊
| 生命科學方案 | 生物與醫學研究、藥物發現與生產的試劑、儀器與耗材。 |
| 分析儀器 | 藥品、生物技術、學術、政府與工業市場的儀器、耗材、軟體與服務。 |
| 專業診斷 | 臨床診斷產品,包括免疫診斷、微生物學與移植診斷。 |
| 實驗室產品與生物醫藥服務 | 實驗室設備、研究與安全市場通路、藥品服務與臨床研究。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1956 | Thermo Electron 成立。 |
| 2006 | Thermo Electron 與 Fisher Scientific 合併,組成 Thermo Fisher Scientific。 |
| 2024 | Thermo Fisher 完成收購蛋白質組學方案提供商 Olink。 |
競爭地位
財務快照
| 總收入 | $44.56B(FY2025 收入) |
| 營業利潤 | $7.75B(FY2025 GAAP 營業利潤) |
| 淨利潤 | $6.70B(FY2025 GAAP 歸屬淨利潤) |
| 稀釋 EPS | $17.74(FY2025 GAAP 稀釋 EPS) |
主要風險
對標普500的重要性
Thermo Fisher Scientific 是權重中等的醫療保健成分股:按權重排名 #45,權重 0.37%(以 Oct 28, 2026 為準),醫療保健板塊內排名 #6。其訂單與服務量被視為生命科學研究支出的指標,並由此反映整個板塊的藥物開發活動。
來源與方法
| 財務、板塊、總部 | Thermo Fisher Scientific 2024 年業績發佈(2025 年 1 月 30 日)及 2024 年 Form 10-K |
| 指數權重與排名 | Slickcharts S&P 500 權重,Oct 28, 2026 收盤,Oct 29, 2026 抓取 |
| 市值 | $260.36B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-29 17:26 · updated 2026-11-15 00:08 · rev 11